Initial ColoSTAT Assessment in UK opens new market access
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Rhythm Biosciences Limited has announced the completion of the first phase of the ColoSTAT assessment by the Southern Hub research laboratory at the Royal Surrey NHS Foundation Trust, marking a significant step towards international market access. The successful technology transfer allows the Hub team to operate the ColoSTAT assay independently, which is crucial for the company's strategy to establish laboratory partnerships globally. The next steps include an analytical evaluation of the assay followed by a clinical study to confirm its reliability in detecting bowel cancer. This development positions Rhythm Biosciences to pursue opportunities beyond Australia, as the company aims to expand its diagnostic capabilities internationally.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Rhythm Biosciences Limited on 6ix
Story so far
Earlier from Rhythm Biosciences
- Initial Director's Interest Notice - Carl Stubbings
- Initial Director's Interest Notice - Maureen Baker
- FY26 Appendix 4E & Audited Financial Report
- Appointment of Non-Executive Directors
- Notification of cessation of securities - RHY
Later from Rhythm Biosciences
- Board Changes
- AGM date and closing date for director nominations
- FY26 Annual Report
- FY26 Appendix 4G and Corporate Governance Statement
- Final Director's Interest Notice - Gavin Fox-Smith
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences